Please use this identifier to cite or link to this item: https://research.matf.bg.ac.rs/handle/123456789/680
DC FieldValueLanguage
dc.contributor.authorNikolić, Zorana Z.en_US
dc.contributor.authorBrajušković, Goran N.en_US
dc.contributor.authorPavićević, Dušanka Lj Savićen_US
dc.contributor.authorKojić, Aleksandar S.en_US
dc.contributor.authorVukotić, Vinka D.en_US
dc.contributor.authorTomović, Saša M.en_US
dc.contributor.authorCerović, Snežana J.en_US
dc.contributor.authorFilipović, Vladimiren_US
dc.contributor.authorMišljenović, Duroen_US
dc.contributor.authorRomac, Stanka P.en_US
dc.date.accessioned2022-08-14T09:49:37Z-
dc.date.available2022-08-14T09:49:37Z-
dc.date.issued2013-01-01-
dc.identifier.urihttps://research.matf.bg.ac.rs/handle/123456789/680-
dc.description.abstractRecent study, which included meta-analysis of two genome-wide association studies (GWAS), followed by a replication, identified the association between single nucleotide polymorphism (SNP) rs3787016 at 19p13 and prostate cancer (PCa) risk. Considering possible genetic differences between populations, we conducted the study in order to evaluate the association of this polymorphism with prostate cancer risk in Serbian population. 261 samples of peripheral blood were obtained from the patients with PCa and 257 samples from patients with benign prostatic hyperplasia (BPH). 106 volunteers who gave samples of bucal swabs comprised the control group. For individuals diagnosed with PCa clinicopathological characteristics including serum prostate-specific antigen (PSA) level at diagnosis, Gleason score (GS) and clinical stage were determined. Genotypization of rs3787016 was performed by using Taqman® SNP Genotyping Assay. The differences in alelle and genotype frequencies between analyzed groups of subjects were performed by using PLINK, SPSS 17.0 for Windows and SNPStats statistical software. No significant association of rs3787016 with PCa risk was determined comparing allele and genotype frequencies among group of patients diagnosed with PCa and the control group, as well as among groups of patients with PCa and BPH. Also, no evidence of association of rs3787016 with PCa risk was shown using tests for association under dominant and recessive genetic models. SNP rs3787016 showed no significant association with standard prognostic parameters regarding PCa progression, nor with the risk of disease progression assessed according to two different risk classification systems.en
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicineen
dc.subjectAssociation studyen
dc.subjectProstate canceren
dc.subjectSingle nucleotide polymorphism (SNP)en
dc.titleAssessment of possible association between rs3787016 and prostate cancer risk in Serbian populationen_US
dc.typeArticleen_US
dc.identifier.scopus2-s2.0-84870368748-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/84870368748-
dc.contributor.affiliationInformatics and Computer Scienceen_US
dc.relation.firstpage57en
dc.relation.lastpage66en
dc.relation.volume6en
dc.relation.issue1en
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptInformatics and Computer Science-
crisitem.author.orcid0000-0002-5943-8037-
Appears in Collections:Research outputs
Show simple item record

SCOPUSTM   
Citations

13
checked on Dec 18, 2024

Page view(s)

12
checked on Dec 24, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.